Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€3.73
25.04.24
-
25.04.25
0.80%
27.04.24

Risky Investment
buy
aTyr Pharma Inc

Start price
Target price
Perf. (%)
€1.66
14.04.24
-
14.04.25
-13.86%
28.04.24

Could be worthwhile Investment >10% per year
Inotiv Inc.

Start price
Target price
Perf. (%)
€5.50
13.04.24
€4.00
13.04.25
-32.36%
27.04.24

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Little Investments for future growth
SELLAS Life Sciences Group Inc

Start price
Target price
Perf. (%)
€1.06
26.03.24
-
26.03.25
-1.69%
31.03.24

Risky Investment
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.05
03.02.24
-
03.02.25
1.90%
17.02.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
PDS Biotechnology Corp.

Start price
Target price
Perf. (%)
€4.08
21.01.24
-
21.01.25
21.10%
03.02.24

Could be worthwhile Investment >10% per year
Palatin Technologies Inc.

Start price
Target price
Perf. (%)
€3.44
20.01.24
€1.00
20.01.25
3.49%
03.02.24

High valuation
Bad rating
Little Investments for future growth
ROE lower than 10% per year
buy
PDS Biotechnology Corp.

Start price
Target price
Perf. (%)
€4.62
07.01.24
-
07.01.25
-11.80%
20.01.24

Could be worthwhile Investment >10% per year
buy
Cellectar BioSciences Inc.

Start price
Target price
Perf. (%)
€2.74
03.01.24
-
03.01.25
-3.65%
06.01.24

Risky Investment
buy
Crossject S.A.

Start price
Target price
Perf. (%)
€4.89
30.12.23
€5.50
30.12.24
-22.39%
10.02.24

Could be worthwhile Investment >10% per year
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€1.06
26.12.23
-
26.12.24
-8.96%
11.01.24

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
AC Immune Ltd

Start price
Target price
Perf. (%)
€4.16
26.12.23
-
26.12.24
-8.05%
19.01.24

Could be worthwhile Investment >10% per year
buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€13.80
10.12.23
€40.00
10.12.24
-19.13%
26.03.24

Could be very worthwhile Investment >20% year
Rising EBIT margin expected
High Investments for future growth
Very valuable balance sheet
buy
Cellectar BioSciences Inc.

Start price
Target price
Perf. (%)
€2.34
02.12.23
€4.00
31.12.25
12.82%
07.01.24

Could be very worthwhile Investment >20% year
Inotiv Inc.

Start price
Target price
Perf. (%)
€2.46
28.11.23
€0.000
28.11.24
26.83%
09.12.23

Risky Investment
EBIT decline > 20% expected
Decining EBIT margin than peer group
High valuation
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.95
11.11.23
-
11.11.24
-
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Bio-Gate AG

Start price
Target price
Perf. (%)
€0.81
05.11.23
-
05.11.24
15.43%
11.11.23

Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
buy
Eledon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.22
29.10.23
€2.80
30.09.25
-
30.10.23

Could be very worthwhile Investment >20% year
CEL-SCI Corp.

Start price
Target price
Perf. (%)
€1.51
23.10.23
-
23.10.24
-23.18%
28.10.23

Could be worthwhile Investment >10% per year
Inotiv Inc.

Start price
Target price
Perf. (%)
€2.32
16.10.23
-
16.10.24
34.48%
11.12.23

Probably not worthwhile Investment
buy
Eledon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€1.28
01.10.23
€2.00
30.09.25
14.84%
29.10.23

Could be very worthwhile Investment >20% year
BioLine RX Ltd ADR

Start price
Target price
Perf. (%)
€1.64
30.09.23
€1.00
30.09.24
-9.76%
14.10.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.12
27.09.23
-
27.09.24
-35.70%
30.09.23

Risky Investment
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.47
26.09.23
-
26.09.24
-26.87%
15.10.23

Could be very worthwhile Investment >20% year
Palatin Technologies Inc.

Start price
Target price
Perf. (%)
€1.81
16.09.23
€1.00
16.09.24
-22.10%
30.09.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
High valuation